Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results ...

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer ...

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with ...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...